Carmentix participated at the SMFM 39th Annual Pregnancy meeting
Carmentix is proud to announce that we have presented our initial clinical results at the Society for Maternal-Fetal Medicine’s 39th Annual Pregnancy meeting from the 11th to 16th February 2019 in Las Vegas. Using our proprietary panel of biomarkers, we have successfully completed the initial phase of our discovery and validation cohort study in a multicenter clinical study at two sites in Melbourne. It was indeed a positive experience to share our results with an esteemed panel of clinicians and researchers.
"We are excited about exposing our results for the first time. After 3 years of development, we have achieved excellent clinical results with a high sensitivity and specificity for preterm birth prediction in both the retrospective and prospective clinical studies. As the feedbacks received during the conference from clinicians were extremely positive, it seems like there will be great anticipation for further results to be released later this year." said CEO of Carmentix, Dr. Nir Arbel.
Details of the abstract can be viewed at: